See more : Shanghai Fudan Forward S&T Co., Ltd (600624.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Oruka Therapeutics Inc. (ORKA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oruka Therapeutics Inc., a leading company in the None industry within the None sector.
You may be interested
- PJSC LUKOIL (LKOH.L) Income Statement Analysis – Financial Results
- coinIX GmbH & Co. KGaA (XCX.DU) Income Statement Analysis – Financial Results
- Taseko Mines Limited (TGB) Income Statement Analysis – Financial Results
- Gold Hydrogen Limited (GHY.AX) Income Statement Analysis – Financial Results
- Alithya Group Inc. (ALYA) Income Statement Analysis – Financial Results
Oruka Therapeutics Inc. (ORKA)
Unable to fetch income statement for: ORKA
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points
Oruka Therapeutics to Present at Multiple November Investor Conferences
MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations...
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration
Source: https://incomestatements.info
Category: Stock Reports